<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biosciences Biotechnology Research Asia</journalTitle>
          <issn>0973-1245</issn>
            <publicationDate>2015-04-28</publicationDate>
    
        <volume>12</volume>
        <issue>1</issue>

 
    <startPage>433</startPage>
    <endPage>444</endPage>

	    <publisherRecordId>5755</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">In Silico Drug Design on Aspirin for Cyclooxygenase I and II, Target for Reduce the Effects of Inflammatory</title>

    <authors>
	 


      <author>
       <name>Ali Kazemi Babaheydari</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	

	

	


	


	
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Department of Medicinal Plants, Researches Centre of Medicinal Plants and Ethno-veterinary, Islamic Azad University, Shahrekord Branch, Shahrekord, Iran</affiliationName>
    

		
		
		
		
		
	  </affiliationsList>






    <abstract language="eng">Aspirin is part of a group of medications called nonsteroidal anti-inflammatory
drugs (NSAIDs), but differs from most other NSAIDs in the mechanism of action.
cyclooxygenases I (COX I) is mainly found in non-inflammatory cells such as cells of the
gastric while the cyclooxygenases II (COX II) are found in inflammatory cells and white
blood cells. COX I inhibition of coagulation disorders in the gastrointestinal adverse
effects. In this paper, we simulated the protein GROMACS force filde, AutoDock (4.2) and
Hex (6.1) try to locate the structural change in aspirin. We purpose making changes in
conformation of aspirin that have a greater impact on COX II. These study the five new
structure aspirin for further investigation. Dynamics analysis and molecular dynamics
(MD) simulation were used to simulate protein-ligand complexes for observing the
interactions and protein variations. The comparative results demonstrated three software
that all the designed compounds have good binding energy when compared with the
binding energies of standard structures such as for docking COX II with Aspirin-S1 (-
5.59), Aspirin-S2 (-5.28), Aspirin-S3 (-3.26), Aspirin-S4 (-4.45) and Aspirin-S5 (-4.44).
Among all the designed compounds, the compound COX II-Aspirin-S1 and S2 indicate
more binding energy g hbond was used to analyze hydrogen bonds. The nonbonded
interaction energies (Lennard-Jones (LJ) and Coulomb terms) were calculated using g
energy.</abstract>

    <fullTextUrl format="html">https://www.biotech-asia.org/vol12no1/in-silico-drug-design-on-aspirin-for-cyclooxygenase-i-and-ii-target-for-reduce-the-effects-of-inflammatory/</fullTextUrl>



      <keywords language="eng">
        <keyword>AutoDock (4.2); cyclooxygenases I; cyclooxygenases II; Molecular dynamics; GROMACS force fild</keyword>
      </keywords>

  </record>
</records>